A Breakthrough Vaccine for Breast and Gastric Cancer is in Trial

A VACCINE that treats one of the most common forms of breast cancer charity is being developed by an Aussie company and one day it could be used to prevent cancer.
The therapy stimulates the body’s own immune system to fight the cancer and studies have showed it produced improved survival rates in mice.
The vaccine will help the one in four women whose breast cancer over expresses the HER2 protein as well as HER2 gastric cancer patients.
Over 1 million cases of gastric cancer are diagnosed each year, mostly in Asia, and the five year survival rate is just 30 per cent.

Trials in Europe have already shown the vaccine is safe and it is now being trialled in Asia on gastric cancer patients.
While researchers hope it will help breast cancer patients, they can’t trial it on these patients in Australia yet.
This is because standard use of the expensive drug Herceptin treatment here would conflict with proving the vaccine works.
Medical University of Vienna researcher Professor Ursula Wiedermann is the co-inventor of the HER-vaxx.

Donate Here: Breast Cancer Donations
If the vaccine works it would most likely be used in combination with chemotherapy, radiation and Herceptin to improve survival, she said.
The idea is that patients with newly diagnosed HER 2 positive cancers would be given the vaccine before any other treatment.
It would stimulate their immune system to fight the cancer then other standard treatments would be loaded on top to kill off the cancer.
Repeat vaccinations would most likely be needed over the patients’ lifetime.
“It’s like tetanus, you need a booster vaccine to keep the memory of the immune system activated,” Professor Wiedermann said.
Eventually the vaccine could be used to try and prevent cancer, Professor Wiedermann said.
“If you had a certain gene and your risk of cancer was high it would make sense to prophylactically vaccinate (vaccines that stimulate an immune response).”
Trials in mice showed the vaccine prolonged the onset of cancerous tumours and once a tumour was established it slowed tumour growth, Professor Wiedermann said.
Armadale-based Australian company Imugene is providing funding to develop the vaccine and run early trials.
Another vaccine against (breast cancer fundraising) developed by researchers based at the Burnett Institute in Melbourne targeted the mucin 1 protein and slashed the rate of breast cancer returning from 60 to just 12 per cent over a 15-year period.
Work on this has stalled because of high costs when only a small number of women got an extension to their lifespan.
Read more research news: RESEARCHERS DISCOVER LINK BETWEEN BACTERIAL LEVELS AND BREAST CANCER
Location: London, UK

Comments

Post a Comment

Popular posts from this blog

Breast Cancer Awareness, Signs and Symptoms

Breast cancer is cancer that forms in the cells of the breasts. After skin cancer, breast cancer is the most common cancer diagnosed in women in the United Kingdom. Breast cancer can occur in both men and women, but it’s far more common in women. Substantial support for breast cancer awareness and  Breast Cancer Research Aid  has helped created advances in the diagnosis and treatment of breast cancer. Breast cancer survival rates have increased, and the number of deaths associated with this disease is steadily declining, largely due to factors such as earlier detection, a new personalized approach to treatment and a better understanding of the disease. Knowing how your breasts normally look and feel is an important part of breast health. Finding breast cancer as early as possible gives you a better chance of successful treatment. But knowing what to look for does not take the place of having regular mammograms and other screening tests. Screening tests can help find breas...
Read more

7 Key Cancer Trends For 2018 | Breast Cancer Research Aid

Image
Issues that will affect the lives of cancer patients in 2018 1. Less chemotherapy A recent report finds that among patients with the most common form of early-stage breast cancer, chemotherapy prescriptions slid, overall, from around 34.5% to 21.3%, in a recent 2-year interval (2013-2015). That’s a huge drop, from over a third of women with stage 1 or 2 disease getting chemo, to just over a fifth taking chemo. This trend is impressive and credible in context of growing discussion and awareness of overtreatment and (although authors of this particular study found no link) wider use and acceptance, among oncologists, of recurrence predictors like OncotypeDx and MammaPrint. The shift for breast cancer is clear. Whether this pattern will emerge and extend to other and less-tracked malignancies, I’m not sure. Probably it will happen variably, by tumor type, and more in the future. 2. More prescription of novel anti-cancer agents Doctors increasingly prescribe targeted drugs f...
Read more

Brave leader in breast cancer support

Image
The more than 500 women who over 20 years were members of the Breast Cancer Charity Support Group of the Bone Marrow Donor Institute, a support group Avis Macphee founded in 1994, will best remember her for her support, friendship, sense of humour, enjoyment of life and willingness to engage in their struggles and provide information to assist us to make treatment decisions. Avis convened meetings in which women revealed diagnoses, planned funerals, mourned the loss of relationships and their hair, exchanged notes on their treating physicians, shared black humour and then laughed afterwards over pasta and garlic bread in a Lygon Street restaurant. The partners of some of those women who died will remember Avis as the woman who offered support and caring and an invitation to dinner after the death of the partner. She was the one who stayed in touch. Researchers will recall Avis as the tireless, well-informed advocate who educated them about the perspectives and experience of w...
Read more